IDRABIOTAPARINUX SODIUM

Details

Stereochemistry	ABSOLUTE
Molecular Formula	C53H79N4O51S8.9Na
Molecular Weight	2051.618
Optical Activity	UNSPECIFIED
Defined Stereocenters	28 / 28
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[H][C@]12CS[C@@H](CCCCC(=O)NCCCCCC(=O)N[C@H]3[C@@H](O[C@@]4([H])[C@H](OC)[C@@H](OC)[C@H](O[C@]5([H])[C@@H](COS([O-])(=O)=O)O[C@H](O[C@@]6([H])[C@H](OC)[C@@H](OC)[C@H](O[C@]7([H])[C@@H](COS([O-])(=O)=O)O[C@H](OC)[C@H](OS([O-])(=O)=O)[C@H]7OS([O-])(=O)=O)O[C@H]6C([O-])=O)[C@H](OS([O-])(=O)=O)[C@H]5OS([O-])(=O)=O)O[C@@H]4C([O-])=O)O[C@H](COS([O-])(=O)=O)[C@@H](OC)[C@@H]3OC)[C@@]1([H])NC(=O)N2

InChI

InChIKey=LJNNVCTYYRPPRZ-GDNXFURLSA-E

InChI=1S/C53H88N4O51S8.9Na/c1-86-30-22(17-93-110(65,66)67)96-48(29(33(30)87-2)56-27(59)15-9-8-12-16-54-26(58)14-11-10-13-25-28-21(20-109-25)55-53(64)57-28)101-36-34(88-3)42(90-5)50(103-40(36)46(60)61)100-32-24(19-95-112(71,72)73)98-52(45(108-116(83,84)85)39(32)106-114(77,78)79)102-37-35(89-4)43(91-6)51(104-41(37)47(62)63)99-31-23(18-94-111(68,69)70)97-49(92-7)44(107-115(80,81)82)38(31)105-113(74,75)76;;;;;;;;;/h21-25,28-45,48-52H,8-20H2,1-7H3,(H,54,58)(H,56,59)(H,60,61)(H,62,63)(H2,55,57,64)(H,65,66,67)(H,68,69,70)(H,71,72,73)(H,74,75,76)(H,77,78,79)(H,80,81,82)(H,83,84,85);;;;;;;;;/q;9*+1/p-9/t21-,22+,23+,24+,25-,28-,29+,30+,31+,32+,33+,34-,35-,36-,37-,38-,39-,40-,41+,42+,43+,44+,45+,48+,49-,50+,51+,52+;;;;;;;;;/m0........./s1

HIDE SMILES / InChI

Molecular Formula	C53H79N4O51S8
Molecular Weight	1844.711
Charge	-9
Count

Stereochemistry	ABSOLUTE
Additional Stereochemistry	No
Defined Stereocenters	28 / 28
E/Z Centers	0
Optical Activity	UNSPECIFIED

Molecular Formula	Na
Molecular Weight	22.9898
Charge	1
Count

Stereochemistry	ACHIRAL
Additional Stereochemistry	No
Defined Stereocenters	0 / 0
E/Z Centers	0
Optical Activity	NONE

Description
Sources: https://www.ncbi.nlm.nih.gov/pubmed/24281408 | https://www.ncbi.nlm.nih.gov/pubmed/24597472

Idrabiotaparinux, a biotinylated idraparinux, was developed by Sanofi as a long-acting inhibitor of factor Xa. Idrabiotaparinux participated in clinical trials phase III to prevent stroke and systemic thromboembolic events in patients with atrial fibrillation. The study was prematurely terminated, because of unknown reason. In addition, the drug was involved in phase II for patients with pulmonary embolism. Sanofi has discontinued development of idrabiotaparinux.

Originator

Approval Year

PubMed

Title	Date	PubMed
Development of idraparinux and idrabiotaparinux for anticoagulant therapy.	2009 Nov	19888513
Efficacy and safety of once weekly subcutaneous idrabiotaparinux in the treatment of patients with symptomatic deep venous thrombosis.	2011 Jan	20946157
Idrabiotaparinux treatment for venous thromboembolism.	2012 Jan 14	22127297

Sample Use Guides

In Vivo Use Guide

Idrabiotaparinux sodium, 3.0 mg, once-weekly for 7 weeks followed a maintenance dosing adjusted according to the age and to the renal function for a minimum total treatment duration of 6 months

Route of Administration: Other

Substance Class	Chemical Created by `admin` on `Sat Dec 16 08:10:28 UTC 2023` Edited by `admin` on `Sat Dec 16 08:10:28 UTC 2023`
Record UNII	K2T918I23K
Record Status	`Validated (UNII)`
Record Version

Download

Name

Type

Language

IDRABIOTAPARINUX SODIUM

Official Name

English

Idrabiotaparinux sodium [WHO-DD]

Common Name

English

idrabiotaparinux sodium [INN]

Common Name

English

Code System Code Type Description

SMS_ID

100000175081